PD-L1 status and clinical outcomes to cabozantinib, sunitinib and everolimus in patients with metastatic clear-cell RCC treated on CABOSUN and METEOR clinical trials.


Conference Paper

Full Text

Duke Authors

Cited Authors

  • Choueiri, TK; Flaifel, A; Xie, W; Braun, D; Ficial, M; Jennings, R; Nassar, A; Escudier, B; George, DJ; Motzer, RJ; Morris, MJ; Powles, T; Wang, E; Huang, Y; Freeman, G; Signoretti, S

Published Date

  • October 2018

Published In

Volume / Issue

  • 29 Suppl 8 /

Start / End Page

  • viii726 -

PubMed ID

  • 32138002

Pubmed Central ID

  • 32138002

Electronic International Standard Serial Number (EISSN)

  • 1569-8041

Digital Object Identifier (DOI)

  • 10.1093/annonc/mdy424.040

Conference Location

  • England